Clinical trial · no report yet · Phase 1/Phase 2
ELECTRA
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05386108 ↗
- Recruiting
- Stemline Therapeutics, Inc.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 6 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases
- Interventions
- Elacestrant; Abemaciclib
- Arms
- Phase 1b Cohort 1 · Experimental
- Phase 1b Cohort 2 · Experimental
- Phase 1b Cohort 3 · Experimental
- Phase 2 · Experimental
- Enrollment
- 73 (estimated)
- Primary outcomes
- Phase 1b: RP2D
- Phase 2: Objective Response Rate (ORR) Per Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
- Sponsor
- Stemline Therapeutics, Inc.
- Start
- Aug 31, 2022
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05386108 · updated Oct 9, 2026